REGN — Regeneron Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $65.88bn
- $59.58bn
- $14.20bn
- 95
- 53
- 40
- 67
Annual cashflow statement for Regeneron Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 3,513 | 8,075 | 4,338 | 3,954 | 4,413 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 297 | 783 | 1,325 | 1,151 | 901 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1,504 | -1,917 | -243 | -94.1 | -618 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 2,618 | 7,081 | 5,015 | 4,594 | 4,421 |
| Capital Expenditures | -615 | -552 | -1,617 | -926 | -882 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 544 | -4,833 | -2,168 | -2,259 | -1,587 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -70.6 | -5,385 | -3,785 | -3,185 | -2,468 |
| Financing Cash Flow Items | -681 | -1,033 | -446 | -701 | -1,063 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1,971 | -1,006 | -1,009 | -1,790 | -2,201 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 577 | 691 | 221 | -382 | -249 |